Feasibility of Prioritizing Drug-Drug-Event Associations Found in Electronic Health Records

被引:27
作者
Banda, Juan M. [1 ]
Callahan, Alison [1 ]
Winnenburg, Rainer [1 ]
Strasberg, Howard R. [2 ]
Cami, Aurel [3 ,4 ]
Reis, Ben Y. [3 ,4 ]
Vilar, Santiago [5 ]
Hripcsak, George [5 ]
Dumontier, Michel [1 ]
Shah, Nigam Haresh [1 ]
机构
[1] Stanford Ctr Biomed Informat Res, MSOB, Stanford, CA 94305 USA
[2] Wolters Kluwer Hlth, San Diego, CA USA
[3] Boston Childrens Hosp, Div Emergency Med, Boston, MA USA
[4] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA
[5] Columbia Univ, Med Ctr, Dept Biomed Informat, New York, NY USA
关键词
LARGE-SCALE PREDICTION; INFORMATION; SAFETY; RECOMMENDATIONS; DATABASE; SIGNALS; SYSTEM;
D O I
10.1007/s40264-015-0352-2
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background and Objective Several studies have demonstrated the ability to detect adverse events potentially related to multiple drug exposure via data mining. However, the number of putative associations produced by such computational approaches is typically large, making experimental validation difficult. We theorized that those potential associations for which there is evidence from multiple complementary sources are more likely to be true, and explored this idea using a published database of drug-drug-adverse event associations derived from electronic health records (EHRs). Methods We prioritized drug-drug-event associations derived from EHRs using four sources of information: (1) public databases, (2) sources of spontaneous reports, (3) literature, and (4) non-EHR drug-drug interaction (DDI) prediction methods. After pre-filtering the associations by removing those found in public databases, we devised a ranking for associations based on the support from the remaining sources, and evaluated the results of this rank-based prioritization. Results We collected information for 5983 putative EHR-derived drug-drug-event associations involving 345 drugs and ten adverse events from four data sources and four prediction methods. Only seven drug-drug-event associations (<0.5 %) had support from the majority of evidence sources, and about one third (1777) had support from at least one of the evidence sources. Conclusions Our proof-of-concept method for scoring putative drug-drug-event associations from EHRs offers a systematic and reproducible way of prioritizing associations for further study. Our findings also quantify the agreement (or lack thereof) among complementary sources of evidence for drug-drug-event associations and highlight the challenges of developing a robust approach for prioritizing signals of these associations.
引用
收藏
页码:45 / 57
页数:13
相关论文
共 39 条
  • [1] [Anonymous], Anatomical Therapeutic Chemical (ATC) Classification
  • [2] Design and validation of an automated method to detect known adverse drug reactions in MEDLINE: a contribution from the EU-ADR project
    Avillach, Paul
    Dufour, Jean-Charles
    Diallo, Gayo
    Salvo, Francesco
    Joubert, Michel
    Thiessard, Frantz
    Mougin, Fleur
    Trifiro, Gianluca
    Fourrier-Reglat, Annie
    Pariente, Antoine
    Fieschi, Marius
    [J]. JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION, 2013, 20 (03) : 446 - 452
  • [3] Toward a complete dataset of drug-drug interaction information from publicly available sources
    Ayvaz, Serkan
    Horn, John
    Hassanzadeh, Oktie
    Zhu, Qian
    Stan, Johann
    Tatonetti, Nicholas P.
    Vilar, Santiago
    Brochhausen, Mathias
    Samwald, Matthias
    Rastegar-Mojarad, Majid
    Dumontier, Michel
    Boyce, Richard D.
    [J]. JOURNAL OF BIOMEDICAL INFORMATICS, 2015, 55 : 206 - 217
  • [4] Automatic Filtering and Substantiation of Drug Safety Signals
    Bauer-Mehren, Anna
    van Mullingen, Erik M.
    Avillach, Paul
    del Carmen Carrascosa, Maria
    Garcia-Serna, Ricard
    Pinero, Janet
    Singh, Bharat
    Lopes, Pedro
    Oliveira, Jose L.
    Diallo, Gayo
    Helgee, Ernst Ahlberg
    Boyer, Scott
    Mestres, Jordi
    Sanz, Ferran
    Kors, Jan A.
    Furlong, Laura I.
    [J]. PLOS COMPUTATIONAL BIOLOGY, 2012, 8 (04)
  • [5] Hospitalisations and emergency department visits due to drug-drug interactions: a literature review
    Becker, Matthijs L.
    Kallewaard, Marjon
    Caspers, Peter W. J.
    Visser, Loes E.
    Leufkens, Hubert G. M.
    Stricker, Bruno HCh
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2007, 16 (06) : 641 - 651
  • [6] Bridging Islands of Information to Establish an Integrated Knowledge Base of Drugs and Health Outcomes of Interest
    Boyce, Richard D.
    Ryan, Patrick B.
    Noren, G. Niklas
    Schuemie, Martijn J.
    Reich, Christian
    Duke, Jon
    Tatonetti, Nicholas P.
    Trifiro, Gianluca
    Harpaz, Rave
    Overhage, J. Marc
    Hartzema, Abraham G.
    Khayter, Mark
    Voss, Erica A.
    Lambert, Christophe G.
    Huser, Vojtech
    Dumontier, Michel
    [J]. DRUG SAFETY, 2014, 37 (08) : 557 - 567
  • [7] Callahan A, 2013, LECT NOTES COMPUTER, V7882, P200
  • [8] Pharmacointeraction Network Models Predict Unknown Drug-Drug Interactions
    Cami, Aurel
    Manzi, Shannon
    Arnold, Alana
    Reis, Ben Y.
    [J]. PLOS ONE, 2013, 8 (04):
  • [9] Dore DD, 2009, CURR MED RES OPIN, V25, P1019, DOI [10.1185/03007990902820519, 10.1185/03007990902820519 ]
  • [10] Literature Based Drug Interaction Prediction with Clinical Assessment Using Electronic Medical Records: Novel Myopathy Associated Drug Interactions
    Duke, Jon D.
    Han, Xu
    Wang, Zhiping
    Subhadarshini, Abhinita
    Karnik, Shreyas D.
    Li, Xiaochun
    Hall, Stephen D.
    Jin, Yan
    Callaghan, J. Thomas
    Overhage, Marcus J.
    Flockhart, David A.
    Strother, R. Matthew
    Quinney, Sara K.
    Li, Lang
    [J]. PLOS COMPUTATIONAL BIOLOGY, 2012, 8 (08)